Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Instem Plc LSE:INS London Ordinary Share GB00B3TQCK30 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -5.00 -0.74% 675.00 670.00 680.00 680.00 675.00 680.00 4,578 15:18:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 25.7 -0.9 -5.7 - 141

Instem Share Discussion Threads

Showing 951 to 973 of 1050 messages
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
DateSubjectAuthorDiscuss
15/7/2019
07:33
Very healthy TU. A good way to take advantage of bio-tech without being exposed to front-line approval risk but taking advantage of that risk by helping make it easier to document. Good on all product fronts at INS including AI mention.
p1nkfish
10/6/2019
15:17
Interesting Chineze news, 4/6/19 - Https://www.instem.com/news/articles/0406-jpimm-selects-provantis.php
p1nkfish
18/4/2019
15:33
thanks P1nk for that link
mw8156
18/4/2019
14:59
Https://aim-watch.com/articles/price-monitoring-extensions-explained/ Taken a long time for this action to occur.
p1nkfish
18/4/2019
14:15
as a lay person what does a first and second price monitoring mean and why is it necessary if only 28000 shares have been traded? this company certainly has potential with its stranglehold on preclinical data software and blue chip client base.
mw8156
12/4/2019
16:29
They mentioned acquisitions too, being on look out, 6-12 months back.
p1nkfish
12/4/2019
15:11
Thanks for that insight, P1NK, hadn't occurred to me, but they did say something about wanting to get more into clinical trial data submission software at their small investor event, seem to recall, rather alarmed that their NTAV is negative and they don't pay any divi so high-risk to that extent especially if a placing is in the offing.
mw8156
12/4/2019
14:49
No new shares issued, just a release of shares to spread holder base. However, I do suspect this could signal a raising being in the offing for an acquisition. Having a wider shareholder base could help considerably if they want to raise a decent sum. Hope they offer pi's a chance to take part if they raise. Also, I think low hanging fruit of acquisitions are gone so size of acquisition likely to be larger and a wider shareholder base then needed, more/deeper pockets to help fund it. Just imho. Dyor.
p1nkfish
11/4/2019
07:43
Placing by two of the founders. They are both non-execs and both look to be in their 70's so I guess it's a good thing in the long term.
wjccghcc
02/4/2019
11:13
Absolutely, less lumpy. Worth a premium for predictability.
p1nkfish
02/4/2019
09:52
Quite big upgrades from N+1 and Progressive. The thing I liked in the results was that the license revenue is down to 15% from 25% as the switch to SaaS increases. Gives more visibility of revenues.
wjccghcc
01/4/2019
21:07
#INS #Instem eyes further growth following upbeat results https://twitter.com/smallcappick/status/1112808520787922945
newtothisgame3
01/4/2019
10:05
Reads well. Solid hold.
p1nkfish
01/4/2019
09:47
satisfactory results by the looks of it and hope they can bill for all the staff taken on; look fairly confident for the year ahead, looking to acquire and have to hope it won't be 'transformational' or if so, small shareholders will be left adrift in the resulting placing.
mw8156
21/3/2019
20:46
Results 1st April.
p1nkfish
15/3/2019
22:32
They dominate the SEND niche from what I can see. Picks & shovels in compliance s/w. Chart looks interesting too currently.
p1nkfish
15/3/2019
22:13
not sure they have much on the balance sheet when one deducts intangibles- suppose it's not unusual in software companies, looks as though the main competitors are all much smaller and not public...
mw8156
15/3/2019
21:39
Very useful - Https://www.instem.com/news/articles/1503-FDA-SEND-3.1-mandate-goes-into-effect.php
p1nkfish
03/3/2019
11:28
Notice of results due too about mid month too.
p1nkfish
03/3/2019
11:27
So important I have to post it twice. MANDATORY. Now who is very well positioned for that I wonder? "The latest version of SEND, as mandated by the US FDA, becomes mandatory for studies starting after 15 March 2019."
p1nkfish
01/3/2019
22:55
mw, important. It could lead to new news. Love the potential in this company. "The latest version of SEND, as mandated by the US FDA, becomes mandatory for studies starting after 15 March 2019."
p1nkfish
06/2/2019
21:53
would have bought more were it not for the possibility of a transformational acquisition and placing in which small investors might have been excluded.
mw8156
06/2/2019
11:17
Would like to see a close > 330p and break above 334p. They keep leaving a trail of crumbs suggesting business is good. Not too surprised as it's a decent picks and shovels software play in pharma. Beats gambling on achieving FDA for a new drug imho,
p1nkfish
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
ADVFN Advertorial
Your Recent History
LSE
INS
Instem
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210518 21:33:20